Medtronic received information via literature regarding anesthesia for percutaneous pulmonary valve implantation.All data were collected retrospectively from a single center between july 2006 to december 2015.The study population included 79 patients (predominantly male, median age 43 years), 50 of which were implanted with medtronic melody transcatheter pulmonary valve.No serial numbers were provided.The literature also included a meta-analysis secondary review of primary data from 7 additional articles in which 771 patients were implanted with melody transcatheter pulmonary valve.No patient demographics or device serial numbers were provided with regards to this meta-analysis.Among all patients, procedural mortality was reported to be 1.6% in the meta-analysis review.However, based on the available information, there was no evidence to suggest that the valve or its function contributed to these deaths.Among all patients, adverse events included: right ventricular outflow tract (rvot) and pulmonary artery (pa) tear and rupture, valve embolization, coronary artery dissection/compression, increased gradient, ventricular tachycardia requiring cardioversion, right bundle branch block (rbbb), third degree atrio-ventricular (av) block, and left ventricle dysfunction.Multiple manufacturers were noted in the literature; based on the available information a direct correlation could not be made between medtronic product and the observed adverse events.Among all patients, access site adverse events included femoral vein hematoma complicated by infection and pseudoaneurysm.Multiple manufacturers were noted in the literature; based on the available information a direct correlation could not be made between medtronic product and the observed malfunction.No additional adverse patient effects or product performance issues were reported.
|